cytospireadmin3467, Author at Cytospire

About cytospireadmin3467

This author has not yet filled in any details.
So far cytospireadmin3467 has created 7 blog entries.

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer

Appointment strengthens Cytospire's executive leadership team as the Company prepares CYT X300 for first-in-human clinical studies

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officercytospireadmin34672026-09-08T06:27:07+00:00

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and LifeArc Ventures

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancercytospireadmin34672026-05-05T13:31:42+00:00